Chanca Piedra Safety, Drug Interactions, and Cautions
Chanca Piedra is generally well-tolerated, with a strong traditional safety record and a low acute toxicity in a rat study of a water extract of the leaves (LD50 > 5,000 mg/kg). The clinically meaningful safety issues are not toxicity but drug interactions — particularly through cytochrome P450 inhibition (especially cytochrome P450 3A4, CYP3A4) and P-glycoprotein effects — and a few hard contraindications (pregnancy, pre-surgical, certain comorbidities). This page is the practical safety reference.
Table of Contents
- General Safety Profile
- Common Side Effects
- Hard Contraindications
- CYP450 Drug Interactions
- P-Glycoprotein Interactions
- Diabetes Medications
- Antihypertensives
- Anticoagulants and Antiplatelets
- Lithium
- Pregnancy and Breastfeeding
- Pre-Surgical Discontinuation
- Key Research Papers
- Connections
- Featured Videos
General Safety Profile
Chanca Piedra has been used traditionally for centuries with no documented pattern of serious adverse effects. Modern clinical trials (ranging from 30 days to 12 months) have reported tolerability comparable to placebo in most studies. Acute toxicity in animal models is very low: in a 2011 study, female rats given a single oral dose of 2,000 or 5,000 mg/kg of a water extract of Phyllanthus niruri leaves showed no signs of toxicity over 14 days, and the authors put the LD50 (the dose that kills half of the animals) above 5,000 mg/kg, well above any clinical dose.
The safety concerns that do exist relate not to direct toxicity but to drug interactions and certain physiologic effects (effects seen in pregnant rats, mild hypotension, mild hypoglycemic effect) that warrant caution in specific populations.
Common Side Effects
Reported in clinical trials and postmarketing surveillance, generally mild and infrequent:
- Stomach upset, mild gastrointestinal (GI) discomfort
- Mild diarrhea, especially at higher doses
- Headache
- Occasional dizziness or postural hypotension (related to mild diuretic and ACE-like effects)
- Mild fatigue (rare)
- Allergic reactions (rare)
Side effects are typically dose-dependent and resolve with dose reduction or discontinuation.
Hard Contraindications
- Pregnancy — no human safety data; in pregnant rats, extracts caused kidney changes in the mothers, oversized fetuses and early physical maturation of pups (see Pregnancy and Breastfeeding below)
- Breastfeeding — insufficient safety data
- Children under 18 — no pediatric dosing established
- Pre-surgical (stop 2 weeks before) — may affect bleeding (mild antiplatelet activity) and blood sugar
- Active hypotension or volume depletion — may worsen low blood pressure
- Severe hepatic or renal impairment — not because the herb is harmful, but because metabolism and clearance change unpredictably; consult clinician
CYP450 Drug Interactions
Chanca Piedra inhibits multiple cytochrome P450 enzymes, with cytochrome P450 3A4 inhibition being mechanism-based (irreversible enzyme suicide). This is the most clinically significant interaction pathway, because cytochrome P450 3A4 metabolizes about 50% of clinically prescribed drugs.
Cytochrome P450 3A4 substrates — caution required:
- Statins (atorvastatin, simvastatin most affected; pravastatin and rosuvastatin less affected)
- Calcineurin inhibitors (tacrolimus, cyclosporine) — narrow therapeutic window; do not combine without specialist guidance
- Human immunodeficiency virus (HIV) protease inhibitors (ritonavir, atazanavir, darunavir)
- Tamoxifen (activation pathway affected)
- Many calcium-channel blockers (amlodipine, diltiazem, verapamil)
- Certain anticonvulsants (carbamazepine)
- Some chemotherapy agents (docetaxel, paclitaxel, vincristine)
- Oral contraceptives (theoretical efficacy reduction or alteration)
- Some benzodiazepines (alprazolam, midazolam)
CYP2C9 substrates:
- Warfarin — can raise international normalized ratio (INR); monitor weekly during initiation
- Phenytoin
- Nonsteroidal anti-inflammatory drugs (ibuprofen, celecoxib)
- Some sulfonylureas
Other CYPs (lesser inhibition): CYP1A2, CYP2D6, CYP2E1 — relevant for caffeine clearance, certain antidepressants, acetaminophen toxicity threshold respectively.
Induction as well as inhibition: In rats, a single 800 mg/kg dose of Phyllanthus amarus extract given 1 hour before oral midazolam raised midazolam’s peak level 3.9-fold and total exposure 9.6-fold through inhibition of CYP3A in the gut, but daily doses of 200 or 800 mg/kg for 15 days increased the activity and expression of liver CYP3A and CYP2B1/2, while CYP1A, CYP2C and CYP2E1 did not change significantly (Taesotikul 2012). In primary human liver cells, Phyllanthus amarus extract and its lignans raised CYP3A4 messenger RNA but inhibited CYP3A4 enzyme activity, while CYP1A2 enzyme activity increased; no CYP1A2 inhibition was detected in a cell-free enzyme test (Husain 2025). The authors of the 2025 study concluded that heavy use could change this enzyme balance and raise the risk of herb-drug interactions.
P-Glycoprotein Interactions
Phyllanthin and hypophyllanthin are direct P-glycoprotein inhibitors in Caco-2 cells. P-gp inhibition raises plasma levels of P-gp-substrate drugs, potentially increasing both efficacy and toxicity:
- Digoxin (narrow therapeutic window; monitor levels)
- Certain calcium-channel blockers
- Some human immunodeficiency virus antiretrovirals
- Certain chemotherapy agents
- Dabigatran (direct oral anticoagulant)
The MRP2 efflux transporter is unaffected, so methotrexate and certain chemotherapy regimens that depend on MRP2 are not affected.
Diabetes Medications
- Insulin and sulfonylureas (glyburide, glipizide, glimepiride) — theoretical additive hypoglycemia; monitor glucose more frequently in the first 2–4 weeks of combination
- Metformin — no documented additive hypoglycemia; mechanistically compatible
- Glucagon-like peptide-1 (GLP-1) agonists, sodium-glucose cotransporter-2 (SGLT2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors — no documented interactions; theoretical additive effect minor
Antihypertensives
Additive blood-pressure-lowering with most antihypertensive classes:
- Angiotensin-converting enzyme inhibitors (lisinopril, enalapril) — mild additive effect
- Angiotensin receptor blockers (losartan, valsartan) — mild additive effect
- Thiazide diuretics — mild additive diuresis
- Calcium-channel blockers — mild additive plus cytochrome P450 3A4 effect on amlodipine and others
- Beta-blockers — minimal interaction
Realistic risk: mild hypotension or dizziness, not crisis. Monitor blood pressure for the first 2–4 weeks of combination. Avoid stacking with potassium-sparing diuretics (spironolactone, eplerenone) in chronic kidney disease (CKD) — theoretical hyperkalemia risk via the ACE-like mechanism.
Anticoagulants and Antiplatelets
- Warfarin — CYP2C9 inhibition can raise international normalized ratio. Check international normalized ratio weekly for the first 3 weeks of any new combination.
- Direct oral anticoagulants (DOACs): apixaban, rivaroxaban, edoxaban — metabolized through cytochrome P450 3A4 (rivaroxaban, apixaban) and P-gp (all). Theoretical risk of elevated drug levels and bleeding.
- Dabigatran — P-gp substrate; theoretical risk of elevated levels.
- Aspirin and clopidogrel — mild theoretical additive antiplatelet effect; clinically minor in most patients.
- Heparin / LMWH — no documented interaction.
Lithium
Mild diuretic effect of Chanca Piedra could increase lithium reabsorption (similar mechanism to thiazides), raising serum lithium levels and risk of toxicity. Monitor lithium serum levels every 2–4 weeks during initiation if combination is unavoidable; consider dose reduction.
Pregnancy and Breastfeeding
There are no human safety data for use in pregnancy or breastfeeding. In a 2020 rat study, a water extract of Phyllanthus niruri given throughout pregnancy at 150, 300 or 600 mg/kg did not cause reproductive toxicity or birth defects, but the 600 mg/kg dose changed the mothers’ kidney weight and structure, and the extract caused oversized fetuses (fetal macrosomia) and more bone-formation sites; the authors concluded that the leaf extract can produce harmful effects during pregnancy. In a 2025 rat study, a water extract given at 75 or 150 mg/kg through pregnancy and breastfeeding caused no significant changes in the mothers’ reproductive measures but changed blood markers of liver function; the male pups’ ear canals and eyes opened early, and as adults they showed anxiety-reducing (anxiolytic-like) behavior. There are no human pregnancy studies of adequate size to assess safety. Breastfeeding data are insufficient. The mild diuretic and hypotensive effects could also affect maternal hemodynamics and milk production.
Pre-Surgical Discontinuation
Stop Chanca Piedra at least 2 weeks before any planned surgery. Reasons:
- Mild antiplatelet activity could affect surgical bleeding
- Mild hypoglycemic effect could complicate perioperative glucose management
- Cytochrome P450 3A4 inhibition could affect anesthesia drug metabolism (especially benzodiazepines, certain anesthetics)
- Mild diuretic effect could complicate fluid management
This is consistent with general herbal-supplement guidelines: most botanicals with active pharmacology should be discontinued 2 weeks before elective surgery.
Key Research Papers
- Taesotikul T, Dumrongsakulchai W, Wattanachai N, et al. (2011). Inhibitory effects of Phyllanthus amarus and its major lignans on human microsomal cytochrome P450 activities: evidence for CYP3A4 mechanism-based inhibition. Drug Metabolism and Pharmacokinetics — PubMed PMID: 21178301
- Taesotikul T, Nakajima M, Tassaneeyakul W, et al. (2012). Effects of Phyllanthus amarus on the pharmacokinetics of midazolam and cytochrome P450 activities in rats. Xenobiotica; the Fate of Foreign Compounds in Biological Systems — PubMed PMID: 22339466
- Sukhaphirom N, Vardhanabhuti N, Chirdchupunseree H, et al. (2013). Phyllanthin and hypophyllanthin inhibit function of P-gp but not MRP2 in Caco-2 cells. The Journal of Pharmacy and Pharmacology — PubMed PMID: 23278697
- Asare GA, Bugyei K, Sittie A, et al. (2012). Genotoxicity, cytotoxicity and toxicological evaluation of whole plant extracts of the medicinal plant Phyllanthus niruri (Phyllanthaceae). Genetics and Molecular Research — PubMed PMID: 22290470
- Asare GA, Addo P, Bugyei K, et al. (2011). Acute toxicity studies of aqueous leaf extract of Phyllanthus niruri. Interdisciplinary Toxicology — PubMed PMID: 22319255
- Paula VG, Cruz LL, Sene LB, et al. (2020). Maternal-fetal repercussions of Phyllanthus niruri L. treatment during rat pregnancy. Journal of Ethnopharmacology — PubMed PMID: 32145330
- Costa Alves MD, Pereira DE, Bidô RCA, et al. (2025). Phyllanthus niruri L. Administration during pregnancy and breastfeeding: Maternal evaluation and effects on initial development and adult behavior of male rat offspring. Brain Research — PubMed PMID: 39694168
- Husain I, Abdulrahman B, Dale OR, et al. (2025). Interaction of Phyllanthus amarus extract and its lignans with human xenobiotic receptors, drug metabolizing enzymes and drug transporters. Journal of Ethnopharmacology — PubMed PMID: 39571700
- Nishiura JL, Campos AH, Boim MA, et al. (2004). Phyllanthus niruri normalizes elevated urinary calcium levels in calcium stone forming (CSF) patients. Urological Research — PubMed PMID: 15221244
- Kaur N, Kaur B, Sirhindi G (2017). Phytochemistry and Pharmacology of Phyllanthus niruri L.: A Review. Phytotherapy Research — PubMed PMID: 28512988
- Ang-Lee MK, Moss J, Yuan CS (2001). Herbal medicines and perioperative care. JAMA — PubMed PMID: 11448284
PubMed Topic Searches
Connections
- All Herbs
- Chanca Piedra Overview
- Kidney Stone Protocol
- Liver Protection and Hepatitis B
- Blood Sugar and Metabolic Effects
- Uric Acid, Gout and Hypertension
- Active Compounds
- Forms, Dosing and Standardization
- Phyllanthus Species Comparison
- History and Traditional Use
- Potassium
- Calcium
- Diabetes
- Blood Sugar
- Comprehensive Metabolic Panel
- Glucagon-Like Peptide-1 Receptor Agonists
Featured Videos